<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775732</url>
  </required_header>
  <id_info>
    <org_study_id>200840</org_study_id>
    <nct_id>NCT04775732</nct_id>
  </id_info>
  <brief_title>Ultra-proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease</brief_title>
  <official_title>Ultra-proactive Therapeutic Drug Monitoring of Infliximab Based on Point-of-care-testing in Inflammatory Bowel Disease: a Pragmatic Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imelda GI Clinical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imelda GI Clinical Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a comparative pragmatic trial in patients with UC and CD on maintenance treatment&#xD;
      with IFX. All IBD patients from cohort A with maintenance IFX treatment at a referral IBD&#xD;
      clinic are prospectively included between June and August 2018. An ultra-proactive IFX TDM&#xD;
      algorithm is applied as follows. All patients have an ELISA TL measurement at baseline, of&#xD;
      which the result determined the follow-up pathway: (A) TL between 3-7μg/mL: continuation at&#xD;
      same dose and interval; (B) TL &gt;7μg/mL: interval prolongation allowed; (C) TL &lt;3μg/mL:&#xD;
      interval shortening with minimum 2 weeks, with the next IFX TL measured using a POCT. (i) If&#xD;
      the POCT showed an IFX TL &lt;3μg/mL, dose was optimized ad hoc using a linear dosing formula&#xD;
      (Dosen = (TL target * Dose n-1) / TL measured), followed by a new POCT test at next visit&#xD;
      with the same interval. (ii) If the POCT showed an IFX TL ≥3µg/mL, no additional dose was&#xD;
      given and routine TL testing with ELISA was retaken at next visit. At every visit this&#xD;
      algorithm was reapplied to all patients.&#xD;
&#xD;
      The patients from cohort A will be compared with the patients from cohort B. The patients in&#xD;
      cohort B receive maintenance IFX treatment at a referral IBD clinic during the same period.&#xD;
      Dose adjustment are done based on standard of care reactive TDM of IFX and clinical symptoms.&#xD;
      Data will be collected retrospectively to avoid treatment optimization bias.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2018</start_date>
  <completion_date type="Actual">September 30, 2019</completion_date>
  <primary_completion_date type="Actual">August 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>pragmatic cluster trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients with infliximab failure</measure>
    <time_frame>one year</time_frame>
    <description>number of patients with infliximab failure after one year (infliximab failure = infliximab discontinuation, IBD related surgery, IBD related hospitalization, add-on IBD treatment, and allergic reaction to infliximab)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>number of TL measurements per patient per year</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of interval changes (shortening, prolongation, bidirectional)</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with infliximab discontinuation</measure>
    <time_frame>one year</time_frame>
    <description>number of patients with discontinuation of infliximab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>percentage of patients with sustained clinical remission</measure>
    <time_frame>one year</time_frame>
    <description>number of patients with physician global assessment &lt;1 and all visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with mucosal remission</measure>
    <time_frame>one year</time_frame>
    <description>number of patients with mucosal remission after one year. (Mucosal remission = simple endoscopic score for CD &lt;3, Rutgeertscore &lt;i2 for, Mayo endoscopic subscore &lt;1 and faecal calprotectin &lt;250 µg/ml. Endoscopy and/or faecal calprotectin between 6 and 12 months after inclusion. If endoscopy and faecal calprotectin at the same moment, then endoscopy was dominant)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">187</enrollment>
  <condition>Crohn Disease</condition>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>ultra proactive arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>reactive arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>infliximab therapeutic drug monitoring</intervention_name>
    <description>dose optimization of infliximab based on a predefined dosing algorithm</description>
    <arm_group_label>reactive arm</arm_group_label>
    <arm_group_label>ultra proactive arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  all adult IBD patients treated for at least 14 weeks with infliximab were included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  induction treatment with infliximab (&lt;14 weeks)&#xD;
&#xD;
          -  treatment with other biological for IBD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Imelda GI clinical research center</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Sint Lucas</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>February 25, 2021</study_first_submitted>
  <study_first_submitted_qc>February 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Imelda GI Clinical Research Center</investigator_affiliation>
    <investigator_full_name>Peter Bossuyt</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>therapeutic drug monitoring</keyword>
  <keyword>inflammatory bowel disease</keyword>
  <keyword>point of care testing</keyword>
  <keyword>infliximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

